Why Rare Disease Drugmakers Are Building Regional Strategies Instead of Global Ones

Rare disease drug development is often discussed as a scientific challenge, but success increasingly depends on navigating a complex global landscape of regulation, commercialization, manufacturing, and market access. While medicines may target the same patients worldwide, the pathways to approval, reimbursement, and adoption differ significantly across regions. The journey of BESREMi® (ropeginterferon alfa-2b), developed by Taiwan-based PharmaEssentia, illustrates how companies must adapt to distinct frameworks in Europe, the United States, and Japan—while simultaneously building the infrastructure needed to support long-term global growth.

A Drug, Three Frameworks, One Question

BESREMi® (ropeginterferon alfa-2b), a long-acting injectable biologic for rare blood cancers developed by Taiwan-headquartered PharmaEssentia Corporation (TWSE: 6446), has received marketing authorization in over 40 countries. It was approved first in Europe in 2019, then the United States in 2021, then Japan in 2023. Each approval came through a different regulatory architecture, at a different pace, on different evidentiary terms — and each shaped what the drug’s developer could and could not do commercially in that market.

That sequence is not a curiosity. It is the central structural fact of global rare disease drug development in the 2020s: the same molecule, evaluated under different frameworks, producing different commercial outcomes, requiring different infrastructure to exploit. How a company navigates those three systems — and what it does next — describes the state of global pharmaceutical collaboration more clearly than any policy document.

PharmaEssentia’s moves across Europe, the United States, and Japan over the past two years offer a detailed case study in that navigation, with a fourth node — the Netherlands — now being constructed to address what the existing architecture cannot yet solve.

Europe: The Licensing Era and Its Limits

Europe approved BESREMi® first, but PharmaEssentia did not commercialize it there directly.

In 2009 — a decade before the drug reached patients — PharmaEssentia exclusively licensed the rights to develop and commercialize ropeginterferon alfa-2b for European, CIS, and Middle Eastern markets to AOP Orphan Pharmaceuticals (now AOP Health), a Vienna-based rare disease specialist. The Phase III PROUD-PV trial that underpinned the European Medicines Agency approval in 2019 enrolled over 260 patients across 14 countries and 50 centers across Europe, generating the clinical evidence base that would eventually support regulatory submissions worldwide, including in the United States and Japan.

The licensing model was the standard playbook for emerging-market biotech entering Europe: partner with a specialist that carries the commercial, regulatory, and logistical overhead of EU market access, share the economics, preserve IP rights for other geographies. AOP Health built BESREMi® into a treatment used by approximately 12,600 patients across Europe, the CIS, and the Middle East.

But the relationship frayed. Beginning in 2017, PharmaEssentia made repeated attempts to terminate the licensing agreement with AOP Health, a process that triggered a cascade of international arbitration proceedings lasting nearly a decade. In February 2025, an International Chamber of Commerce tribunal issued a partial final award in AOP Health’s favor, finding PharmaEssentia liable for intentional breaches. In April 2026, the Frankfurt Higher Regional Court dismissed PharmaEssentia’s application to set aside that award and declared it enforceable, though an appeal to the German Federal Court of Justice remains possible. At its May 2026 investor conference, PharmaEssentia stated it hopes to resolve the AOP arbitration through negotiation.

What the protracted dispute illustrates about the European framework is structural: the licensing model that gives smaller biotechs access to European markets also creates long-term governance dependencies that can be difficult and costly to exit. For companies seeking to evolve from licensors to direct operators in Europe — particularly as their commercial scale grows — the pathway is legally complex and operationally demanding.

The Netherlands Node: Direct Control, Built From Scratch

Against that backdrop, PharmaEssentia’s board approval in May 2026 to establish a wholly-owned subsidiary in the Netherlands, paired with a dedicated quality testing laboratory, represents something more specific than a geographic expansion. It represents a deliberate effort to construct direct European operational infrastructure while the AOP licensing relationship remains legally unresolved.

The Netherlands choice reflects the EU’s emerging position as a pharmaceutical logistics and regulatory hub. The country hosts the European headquarters of dozens of multinational life sciences firms — Astellas, Biogen, Novo Nordisk, and Takeda maintain major European operations there — and benefits from both Schiphol Airport’s status as one of Europe’s busiest air freight hubs and Rotterdam’s position as the continent’s largest seaport. For biologics requiring cold-chain distribution and rapid customs clearance, the Netherlands offers operational advantages that few European jurisdictions match.

But the quality lab component of the announcement carries equal weight. By building a quality testing facility in the Netherlands and integrating it into PharmaEssentia’s global quality assurance architecture as a backup node, the company reduces its dependence on any single site — a supply resilience strategy that mirrors what it is simultaneously building in Puerto Rico for the U.S. market. The Netherlands lab is explicitly described as part of a global quality system redundancy architecture, designed to diversify single-point-of-failure risk.

What the Netherlands move signals more broadly is the direction the EU’s own regulatory posture is pushing companies. The European Commission’s Pharmaceutical Strategy for Europe, implemented progressively since 2020, places explicit emphasis on supply chain resilience, localized manufacturing capacity, and direct regulatory engagement by marketing authorization holders. A company seeking to grow within that framework needs a direct EU operational presence — not a licensing proxy — to engage with the EMA, national health authorities, and hospital formulary systems on its own terms.

The United States: Infrastructure Before Approval

The U.S. commercial story for BESREMi® begins not with the November 2021 FDA approval but with the decisions made years before it — decisions that shaped how quickly the drug could convert regulatory clearance into commercial revenue.

PharmaEssentia USA Corporation is headquartered in Burlington, Massachusetts, positioning the subsidiary inside the Boston corridor that concentrates a disproportionate share of U.S. oncology and hematology opinion leadership, academic medical centers, and specialist prescriber networks. The location was deliberate: the drug’s primary indication, polycythemia vera, is managed overwhelmingly by hematologists at academic and community cancer centers, and Boston anchors the clinical relationships those sales teams need.

Throughout 2025, the company significantly expanded its U.S. commercial and medical affairs teams, building out the infrastructure needed not just for the existing polycythemia vera indication but for a potential second: essential thrombocythemia (ET). The FDA has set an August 30, 2026 target date to complete its review of a supplemental BLA for the ET indication. In May 2026, the company appointed Eric Vogel — formerly Group Vice President of Sales and Marketing at Incyte Corporation, with direct MPN market experience — as U.S. Head of Commercialization, a hire timed to anticipate rather than react to a potential approval.

The pattern — building commercial teams, deploying senior hires, and staging medical affairs ahead of regulatory decisions rather than after — reflects something the U.S. pharma market rewards and the FDA’s own communications increasingly encourage: companies that demonstrate launch-readiness at the time of approval generate faster patient access, which regulators track as a real-world outcome metric.

The second U.S. dimension is manufacturing. In February 2026, PharmaEssentia announced a board-approved investment of approximately US$46 million (~NT$1.44 billion) to establish a wholly-owned manufacturing subsidiary in Toa Baja, Puerto Rico, with operations planned to begin in 2027. In March, the investment agreement was formalized at a ceremony attended by Puerto Rico Governor Jenniffer González Colón, the U.S. Department of Commerce Director for Puerto Rico, and the Director General of the Taipei Economic and Cultural Office in Miami — a guest list that underscored the diplomatic as well as commercial dimensions of the move.

Puerto Rico sits inside the U.S. FDA’s regulatory perimeter, meaning products manufactured there ship to U.S. patients without additional cross-border clearances. The facility will be built to the same quality standards as the Taichung, Taiwan manufacturing site, and Puerto Rico staff will complete intensive training there before operations begin. Personnel from the original site transfer knowledge; the new site diversifies supply risk. The structure — identical quality standards, geographically distributed — is what the FDA’s own post-pandemic supply chain resilience guidance recommends.

Japan: Precision Regulation and the Value of Speed

Japan’s path to BESREMi® approval was the most methodical of the three. The Pharmaceuticals and Medical Devices Agency (PMDA) required a dedicated Phase II clinical study conducted specifically in Japanese patients — the A19-201 study — alongside the global Phase III PROUD-PV data before granting approval for polycythemia vera in March 2023. The PMDA’s insistence on Japan-specific data, a longstanding feature of its regulatory philosophy, extends approval timelines but produces a different downstream outcome: Japanese physicians receive approval supported by evidence drawn from their own patient population, which affects prescribing confidence and adoption rates.

That approval gave BESREMi® what industry observers call a “regulatory trifecta” — EMA, FDA, and PMDA — a combination that functions as a credibility signal in every subsequent market where the drug has not yet been evaluated. When regulators in Southeast Asia, Latin America, or the Middle East assess a drug lacking local clinical data, they routinely reference the EMA, FDA, and PMDA determinations as proxies. Completing all three narrows the evidentiary gap that slows access in smaller markets.

In February 2026, Japan extended that engagement further. The PMDA approved a high-dose dosing regimen (HIDAT) for BESREMi®, allowing patients to reach the clinical target dose of 500 micrograms in as few as four weeks — compared to the original protocol, under which reaching that dose could take months of graduated increases. The PMDA’s willingness to update the label to reflect optimized dosing data, relatively quickly after the initial approval, reflects a shift in the agency’s post-approval engagement posture. Earlier disease control typically correlates with better patient outcomes, and that outcome data feeds back into the clinical record.

Japan is also one of two markets — alongside the U.S. — where PharmaEssentia operates a direct commercial team rather than working through a local partner. The scale effects of expanding those teams in 2025 are explicitly cited in the company’s investor communications as a driver of current revenue growth.

The Clinical Evidence Flywheel: ASCO, EHA, and the Data Network

One structural feature of the global rare disease market that each of these regional moves depends on is the international conference circuit for oncology and hematology evidence. Clinical data presented at the American Society of Clinical Oncology (ASCO) annual meeting shapes U.S. prescribing norms. Data at the European Hematology Association (EHA) congress shapes European ones. The PMDA reviews both. Regulators in markets from Brazil to South Korea reference both as inputs.

In May 2026, PharmaEssentia announced five presentations at both the ASCO annual meeting in Chicago and the EHA 2026 Congress in Stockholm, presenting new analyses from the Phase 3 SURPASS-ET trial of ropeginterferon alfa-2b in essential thrombocythemia, including two-year outcome data on early versus delayed treatment initiation. The simultaneous deployment of clinical evidence into both the U.S. and European scientific conversations — timed to coincide with a pending FDA decision on the ET indication — is not coincidental scheduling. It is the operating logic of a company that understands its regulatory submissions are influenced by the scientific discourse its clinical data generates, and that discourse is global.

The Blueprint Assembled

Reading these moves together, across four geographies and roughly seven years of sustained execution, a pattern becomes visible.

Europe came first and provided the clinical evidence base — the PROUD-PV trial data that supported not just the EMA’s 2019 decision but every subsequent regulatory submission worldwide. The licensing model that made European development possible also created dependencies that the company is now working, through both legal channels and direct infrastructure investment in the Netherlands, to rebalance. What Europe’s regulatory framework demanded — rigorous multi-country clinical evidence, direct quality oversight, supply chain presence — is now being built in.

The United States provided the commercial proof of concept. The FDA’s approval in 2021 opened the market that generates the majority of BESREMi®’s current revenue. The U.S. framework’s emphasis on commercial launch-readiness and post-approval evidence generation pushed the company to build the kind of commercial organization — Burlington headquarters, expanded field teams, senior commercial hires timed to pending approvals, U.S.-territory manufacturing — that the market rewards with rapid adoption. The Puerto Rico facility, due for operations in 2027, transforms the U.S. from a pure commercial market into a manufacturing node.

Japan validated the clinical profile for the global prescriber community. The PMDA’s patient-population-specific evidentiary requirements produced data that strengthens the drug’s credibility in every market that lacks local clinical studies of its own. Japan’s willingness to update the label rapidly with optimized dosing data keeps that clinical profile current.

The Netherlands, the newest node, completes a circuit. It gives the company direct regulatory standing in the world’s most extensive rare disease market, quality backup infrastructure for European supply, and operational independence from a licensing relationship that is currently being resolved through German courts.

Each region built something different. The question the next phase will answer is whether the whole proves more valuable than the sum of those parts — and whether the supply chain, regulatory, and clinical architecture assembled across them holds together as the drug’s approved indications expand.

Author

Bernice Lottering

Related Post

Interviews

As Real-World Evidence Gains Ground in Oncology, Where Does Flatiron Health Fit In?

2026-05-05

Trials & Approvals

FDA Approves Johnson & Johnson’s Novel Oral Peptide for Psoriasis Treatment

2026-03-19

Markets & Deals

Gilead Acquires Arcellx for $7.8B to Advance Anito-cel in Multiple Myeloma

2026-02-24